PART I We are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Our focus is primarily on developing innovative therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. (Apimeds Korea) in South Korea as Apitoxin for the treatment of OA. Apimeds US is not associated with the market, sale and revenues g...
Q2 FY2026 — expected 2026-07-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001213900-25-032206 | EDGAR | 45K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001213900-25-109280 | EDGAR | 18K words |
| 2025-08-19 | 2025-06-30 | 0001213900-25-078507 | EDGAR | — |
| 2025-05-20 | 2025-03-31 | 0001213900-25-045588 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001213900-26-034786 | EDGAR | 2K words |
| 2026-03-25 | 0001213900-26-033832 | EDGAR | — |
| 2026-03-16 | 0001213900-26-028332 | EDGAR | — |
| 2026-01-02 | 0001213900-26-000464 | EDGAR | — |
| 2025-12-10 | 0001213900-25-119894 | EDGAR | — |
| 2025-12-02 | 0001213900-25-117173 | EDGAR | — |
| 2025-11-18 | 0001213900-25-112184 | EDGAR | — |
| 2025-10-16 | 0001213900-25-099553 | EDGAR | — |
| 2025-07-16 | 0001213900-25-064446 | EDGAR | — |
| 2025-06-05 | 0001213900-25-051567 | EDGAR | — |
28 total filings indexed. 14 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001894525 |
| Ticker | APUS |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.apimedsus.com |
| Listed | 2025-05-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report